Antonelli Guido, Scagnolari Carolina, Moschella Federica, Proietti Enrico
Department of Molecular Medicine, Pasteur Institute-Cenci Bolognetti Foundation, Sapienza University, Rome, Italy.
Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Cytokine Growth Factor Rev. 2015 Apr;26(2):121-31. doi: 10.1016/j.cytogfr.2014.12.006. Epub 2014 Dec 30.
The clinical exploitation of type I interferon (IFN) as an antiviral and antineoplastic agent is based on the properties originally attributed to this cytokine family, with schedules reflecting only their antiviral and antiproliferative activities. Nevertheless, type I IFN has emerged as a central activator of the innate immunity. As current schedules of treatment for chronic hepatitis C and for hematological and solid tumors, based on the continuous administration of recombinant type I IFN or pegylated formulations, disregard viral resistance, host genetic variants predicting treatment outcome and mechanisms of refractoriness, new administration schedules, the combination of type I IFN with new drugs and the increased monitoring of patients' susceptibility to type I IFN are expected to provide a new life to this valuable cytokine.
I型干扰素(IFN)作为一种抗病毒和抗肿瘤药物的临床应用是基于最初赋予该细胞因子家族的特性,其给药方案仅反映了它们的抗病毒和抗增殖活性。然而,I型干扰素已成为先天免疫的核心激活剂。由于目前基于持续给予重组I型干扰素或聚乙二醇化制剂的慢性丙型肝炎、血液系统肿瘤和实体瘤的治疗方案忽视了病毒耐药性、预测治疗结果的宿主基因变异以及难治性机制,新的给药方案、I型干扰素与新药的联合使用以及对患者对I型干扰素敏感性的加强监测有望为这种有价值的细胞因子带来新的生机。